Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 2 December 2005:
Vol. 310. no. 5753, pp. 1442 - 1443
DOI: 10.1126/science.1122009
Prev | Table of Contents | Next

Perspectives

IMMUNOLOGY:
Tipping the Scales Toward More Effective Antibodies

Jenny M. Woof

Immunoglobulin G molecules, key mediators of immune protection and burgeoning therapeutic reagents, exist in different forms or subclasses. In her Perspective, Woof discusses new work by Nimmerjahn and Ravetch that reveals how, in some settings, the in vivo functional capabilities of each subclass may be predicted on the basis of differential interaction with specific cellular Fc receptors.

The author is in the Division of Pathology and Neuroscience, University of Dundee Medical School, Ninewells Hospital, Dundee DD1 9SY, UK. E-mail: j.m.woof{at}dundee.ac.uk

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of 86Y- and 111In-Antimindin/RG-1, Engineered Antibody Fragments in LNCaP Tumor-Bearing Nude Mice.
D. W. Schneider, T. Heitner, B. Alicke, D. R. Light, K. McLean, N. Satozawa, G. Parry, J. Yoo, J. S. Lewis, and R. Parry (2009)
J. Nucl. Med. 50, 435-443
   Abstract »    Full Text »    PDF »
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
M. Peipp, J. J. Lammerts van Bueren, T. Schneider-Merck, W. W. K. Bleeker, M. Dechant, T. Beyer, R. Repp, P. H. C. van Berkel, T. Vink, J. G. J. van de Winkel, et al. (2008)
Blood 112, 2390-2399
   Abstract »    Full Text »    PDF »
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies.
M. Dechant, W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J. J. Lammerts van Bueren, W. K. Bleeker, P. W.H.I. Parren, J. G.J. van de Winkel, et al. (2008)
Cancer Res. 68, 4998-5003
   Abstract »    Full Text »    PDF »
Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor.
M. Dechant, T. Beyer, T. Schneider-Merck, W. Weisner, M. Peipp, J. G. J. van de Winkel, and T. Valerius (2007)
J. Immunol. 179, 2936-2943
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)